Amide-Substituted Heteroaryl Compounds for Tyk2 Cytokine Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, and lupus, are limited in effectively modulating IL-12, IL-23, and IFNα signaling pathways, which are crucial in autoimmunity.
Innovation Solution
Development of amide-substituted heterocyclic compounds that inhibit Tyk2-mediated signal transduction, modulating IL-12, IL-23, and IFNα cytokines to treat autoimmune and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then existing therapeutic options are available, but they are limited in effectively modulating IL-12, IL-23, and IFNα signaling pathways
Solution Approach 1:
The patent modifies the chemical structure by varying parameters such as the heteroaryl group (R2), substituent positions, and molecular weight range (150-500 Da) to optimize the compounds' ability to inhibit Tyk2 and modulate IL-12, IL-23, and IFNα signaling pathways effectively across different autoimmune diseases
Solution Approach 2:
The developed compounds are designed to simultaneously target multiple cytokine signaling pathways (IL-12, IL-23, and IFNα) through Tyk2 inhibition, providing a universal treatment approach for various autoimmune and inflammatory diseases including psoriasis, Crohn's disease, lupus, and multiple sclerosis
Data Source
AI summary
Compounds having the following formula I:or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.